Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 6, 2007, Pages

  Graciano, Miguel L ^a   Mouton, Cynthia R ^a   Patterson, Matthew E ^a   Seth, Dale M ^a   Mullins, John J ^b   Mitchell, Kenneth D ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Glomerulosclerosis; Immunohistochemistry; Kidney; Peptide hormones; Renal injury; Renal pathology; Renin angiotensin system

Indexed keywords

3 INDOLEMETHANOL; ANGIOTENSIN II; CYCLINE; CYTOCHROME P450 1A1; RENIN; REN2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GLOMERULAR DYSFUNCTION; IMMUNOHISTOCHEMISTRY; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY PARENCHYMA; KIDNEY TUBULE CELL; MACROPHAGE; MALE; MALIGNANT HYPERTENSION; MEAN ARTERIAL PRESSURE; NEPHRITIS; NONHUMAN; PATHOGENESIS; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STAINING; TRANSGENIC RAT; ANIMAL; ARTERIOLE; BLOOD PRESSURE; BLOOD VESSEL; BODY WEIGHT; DIET; GENETICS; GLOMERULUS; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY CIRCULATION; MOUSE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC ANIMAL;

ANGIOTENSIN II; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARTERIOLES; BLOOD PRESSURE; BLOOD VESSELS; BODY WEIGHT; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; DIET; HYPERTENSION, MALIGNANT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY CORTEX; KIDNEY GLOMERULUS; MALE; MICE; NEPHRITIS, INTERSTITIAL; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RENAL CIRCULATION; RENIN;

EID: 34447646491     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00469.2006     Document Type: Article

References (50)

1. Aizawa T, Ishizaka N, Kurokawa Nagai R K, Nakajima H, Taguchi J, Ohno M. Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int 59: 645-653, 2001.
2. Bidani AK, Griffin KA. Long term consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens 11: 73-80, 2002.
3. Bidani AK, Griffin KA, Plott W, Schwartz MM. Renal ablation acutely transforms 'benign' hypertension to 'malignant' nephrosclerosis in hypertensive rats. Hypertension 24: 309-316, 1994.
4. Bledsoe G, Shen B, Yao Y, Zhang JJ, Chao L, Chao J. Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther 17: 545-555, 2006.
5. Bloudickova S, Rajnoch J, Loderova A, Honsova E, Viklicky O. Mycophenolate mofetil ameliorates accelerated progressive nephropathy in rat. Kidney Blood Press Res 29: 60-66, 2006.
6. Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. J Pharmacol Exp Ther 316: 8-16, 2006.
7. Campbell SJ, Carlotti F, Hall PA, Clark AJ, Wolf CR. Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 109: 2619-2625, 1996.
8. Cheng ZJ, Finckenberg P, Louhelainen M, Merasto S, Tikkanen I, Vapaatalo H, Mervaala EM. Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). Eur J Pharmacol 461: 159-169, 2003.
9. Eng E, Veniant M, Floege J, Fingerle J, Alpers CE, Menard J, Clozel JP, Johnson RJ. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens 7: 177-185, 1994.
10. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, Wolf CR. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281: 359-368, 1992.
11. Fujihara CK, Avancini Costa Malheiros DM, de Lourdes Noronha I, de Nucci G, Zatz R. Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 37: 170-175, 2001.
12. Fujihara CK, Noronha IL, Malheiros DMAC, Antunes GR, Oliveira IB, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11: 283-290, 2000.
13. Fujii-Kuriyama Y, Imataka H, Sogawa K, Yasumoto K, Kikuchi Y. Regulation of CYP1A1 expression. FASEB J 6: 706-710, 1992.
14. Gelboin HV. Benzopyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev 60: 1107-1166, 1980.
15. Gonçalves RG, Gabrich L, Rosario A Jr, Takiva CM, Ferreira ML, Chiarini LB, Persechini PM, Coutinho-Silva R, Leite M Jr. The role of purinergic P2X(7) receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 70: 1599-1606, 2006.
16. Graciano ML, Cavaglieri RC, Delle H, Dominguez WV, Casarini DE, Malheiros DMA, Noronha IL. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 15: 1805-1815, 2004.
17. Haller H, Park JK, Dragun D, Lippoldt A, Luft FC. Leukocyte infiltration and ICAM-1 expression in two-kidney one-clip hypertension. Nephrol Dial Transplant 12: 899-903, 1997.
18. Hilgers KF, Hartner A, Porst M, Veelken R, Mann JF. Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. Circulation 104: 1436-1440, 2001.
19. Howard LL, Patterson ME, Mullins JJ, Mitchell KD. Salt-sensitive hypertension develops after transient induction of ANG II-dependent hypertension in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol 288: F810-F815, 2005.
20. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47: 1075-1083, 2006.
21. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 45: 1129-1136, 1993.
22. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM. Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474, 1992.
23. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, Mullins JJ. Controlled hypertension, a toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 276: 36727-36733, 2001.
24. Kobayashi S, Ishida A, Moriya H, Mori N, Fukuda T, Takamura T. Angiotensin II receptor blockade limits kidney injury in two-kidney, one-clip Goldblatt hypertensive rats with special reference to phenotypic changes. J Lab Clin Med 133: 134-143, 1999.
25. Kopkan L, Majid DSA. Superoxide contributes to development of salt sensitivity and hypertension induced by nitric oxide deficiency. Hypertension 46: 1026-1031, 2005.
26. Loub WD, Wattenberg LW, Davis DW. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 54: 985-988, 1975.
27. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal ANG II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin-Angiotensin-Aldosterone System 7: 74-86, 2006.
28. Mitchell KD, Mullins JJ. Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 289: F1210-F1216, 2005.
29. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35: 193-201, 2000.
30. Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, Cortijo J, Morcillo EJ, Sanz MJ. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110: 3581-3586, 2004.
31. Opay AL, Mouton CR, Mullins JJ, Mitchell KD. Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 291: F612-F618, 2006.
32. Patterson ME, Mouton CR, Mullins JJ, Mitchell KD. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 289: F754-F759, 2005.
33. Pelkonen O, Nebert DW. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev 34: 189-222, 1982.
34. Piqueras L, Kubes P, Alvarez A, O'Connor E, Issekutz AC, Esplugles JV, Sanz MJ. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT1 and AT2 receptor-mediated P-selectin upregulation. Circulation 102: 2118-2123, 2000.
35. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 23: 401-409, 2005.
36. Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, , Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001.
37. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats. Am J Nephrol 24: 587-594, 2004.
38. Rodriguez-Iturbe B, Quiroz Y, Kin CH, Vaziri ND. Hypertension induced by aortic coarctation above the renal arteries is associated with immune cell infiltration of the kidneys. Am J Hypertens 18: 1449-1456, 2005.
39. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-F201, 2002.
40. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT1 and AT2 receptors. Am J Pathol 158: 1743-1756, 2001.
41. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 82: 12-22, 2002.
42. Sironi L, Gelosa P, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 311: 989-995, 2004.
43. Smith JD, Wong E, Ginsberg M. Cytochrome P450 1A1 promoter as a genetic switch for the regulatable and physiological expression of a plasma protein in transgenic mice. Proc Natl Acad Sci USA 92: 11926-11930, 1995.
44. Stewart T, Jung FF, Manning J, Vehaskari VM. Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int 68: 2180-2188, 2005.
45. Uitimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63: 209-216, 2003.
46. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 13: 93-99, 2004.
47. Whitworth CE, Fleming S, Cumming AD, Morton JJ, Burns NJ, Williams BC, Mullins JJ. Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. Kidney Int 46: 1528-1532, 1994.
48. Whitworth CE, Fleming S, Kotelevtsev Y, Manson L, Brooker GA, Cumming AD, Mullins JJ. A genetic model of malignant phase hypertension in rats. Kidney Int 47: 529-535, 1995.
49. Wilcox CS, Welch WJ. Oxidative stress: cause or consequence of hypertension. Exp Biol Med (Maywood) 226: 619-620, 2001.
50. Zou LX, Imig JD, von Thun AM, Hymel A, Ono H, Navar LG. Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. Hypertension 28: 669-677, 1996.